Prevention and management of CMV-related problems after hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 29, Issue 8, 2002, Pages 633-638

  Zaia, J A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Management; Prevention; Stem cell transplantation

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; CORTICOSTEROID; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; NUCLEIC ACID; THYMOCYTE ANTIBODY; VALACICLOVIR; VIRUS DNA; CYTOSINE; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; IMMUNOASSAY; IMMUNOLOGICAL PROCEDURES; INFECTION RISK; MEDICAL DECISION MAKING; NEPHROTOXICITY; NEUTROPENIA; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT PLANNING; VIRUS CULTURE; VIRUS DETECTION; VIRUS HYBRID; VIRUS REPLICATION; CYTOMEGALIC INCLUSION BODY DISEASE; ISOLATION AND PURIFICATION; REVIEW; RISK FACTOR;

ACYCLOVIR; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; FOSCARNET; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RISK FACTORS;

EID: 0036015533     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703407     Document Type: Article

References (54)

1. Nonbacterial pneumonia after allogeneic marrow transplantation. A review of ten years experience
2. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
3. Risk factors for cytomegalovirus infection after human marrow transplantation
4. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation
5. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using T-cell depletion with anti-thymocyte globulin
6. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants
7. High rate of secondary viral and bacterial infections in patients undergoing allogenic bone marrow mini-transplantation
8. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality
9. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant
10. Increased incident of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
11. Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multible myeloma: No evidence of increased incidence based on polymerase-chain-reaction monitoring
12. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
13. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: Prevention and therapy
14. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen
15. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
16. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: Comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture
17. Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogenic stem cell transplant
18. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease
19. Nucleic acid sequence-based amplification
20. Prediction of cytomegalovirus pneumonia after marrow transplantation from cellular characteristics and cytomegalovirus culture of bronchoalveolar lavage fluid
21. Comparison of cytomegalovirus (CMV) antigenemia and CMV in bronchoalveolar lavage fluid for diagnosis of CMV pulmonary infection after bone marrow transplantation
22. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
23. Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays
24. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients
25. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
26. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: Long-term follow-up
27. Prevention of cytomegalovirus disease after allogeneic marrow transplant by ganciclovir prophylaxis
28. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease risk factors and outcome
29. Recovery of HLA-restricted cytomegalovirus (CMV) specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
30. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
31. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
32. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients
33. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients
34. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir
35. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients
36. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
37. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
38. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
39. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation
40. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients
41. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation
42. Use of oral ganciclovir (PO-GCV) for the preemptive treatment (TX) of CMV following allogeneic HCT: Safety and feasibility results
43. Intravenous immunoglobulin (IVIG): Appropriate indications and uses in hematopoietic stem cell transplantation
44. Cytotoxic T-cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic response correlate with recovery from cytomegalovirus in bone marrow recipients
45. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
46. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation
47. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease
48. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation
49. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection
50. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation
51. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
52. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65
53. T-cell therapy for chemotherapy-refractory CMV infection
54. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries